TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05421858: A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.

Sponsor: Basilea Pharmaceutica · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 450 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,630,088

Rescue Site Savings

+$2,404,344

Unlock Full NCT05421858 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05421858 Rescue Dossier →